Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE

Documenti analoghi

• Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients
  di: Cohen, C, et al.
  Pubblicazione: (2010)
• Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials
  di: Nelson, M, et al.
  Pubblicazione: (2010)
• Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation
  di: van ′t Klooster, Gerben, et al.
  Pubblicazione: (2010)
• Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
  di: Nelson, Mark, et al.
  Pubblicazione: (2012)
• Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug
  di: McLeay, Sarah C., et al.
  Pubblicazione: (2014)